TG Therapeutics raises funds for cancer combination drugTG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month Share XTG Therapeutics raises funds for cancer combination drughttps://pharmaphorum.com/news/tg-therapeutics-set-for-upsized-ipo-to-develop-cancer-combination-drug/
CLL patients in England to get AZ’s Calquence after okay from NICENHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic Share XCLL patients in England to get AZ’s Calquence after okay from NICEhttps://pharmaphorum.com/news/cll-patients-in-england-to-get-azs-calquence-after-okay-from-nice/
TG Therapeutics challenges Roche with FDA filing for CLL drugUS biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic Share XTG Therapeutics challenges Roche with FDA filing for CLL drughttps://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/
NICE backs chemo-free CLL combination from AbbVie and RochePreviously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE Share XNICE backs chemo-free CLL combination from AbbVie and Rochehttps://pharmaphorum.com/news/nice-backs-chemo-free-cll-combination-from-abbvie-and-roche/
AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalAbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can Share XAbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalhttps://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
AstraZeneca ends another Calquence trial earlyFor the second time in the space of a month AstraZeneca has stopped a trial of its chronic Share XAstraZeneca ends another Calquence trial earlyhttps://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/
